The midcap pocket of the Indian market has quietly become the arena where a lot of the real action is playing out. While the headline Nifty has had its share of attention, foreign institutional investors have been doing the harder work of combing through midcaps and taking positions in names where the earnings arc looks fresher than the index average. September 2026 quarter filings now show these flows clearly.
Midcaps are an interesting hunting ground. The companies are large enough to clear basic liquidity and governance hurdles that make small caps tricky, yet still small enough that an earnings re-rating or a business transition can move the needle in a way that is harder to engineer in a Nifty-50 stock. The names below fit that spirit; each is midcap, and each attracted fresh FII money last quarter.
PVR INOX is India's largest film-exhibition company and operates the familiar PVR and INOX cinema brands under one roof following the 2023 merger of PVR Limited and INOX Leisure. PVR's parentage dates back to 1995, and the company now runs a pan-India network of multiplexes across metros, Tier-2, and increasingly Tier-3 markets.
The business model has steadily shifted toward a capital-light posture through FOCO (franchise-owned, company-operated) and asset-light screen expansion, allowing the company to scale screens without the balance-sheet strain of pure lease additions. Alongside film exhibition, PVR INOX has been broadening into live sports screenings, concerts, standup shows and other out-of-home entertainment formats, with the recent IPL and FIFA World Cup 2026 live streaming at theatres being an example of this shift.
PVR INOX reported a strong Q1 FY27, with revenue growing 12% YoY to Rs 16,420 m and EBITDA nearly doubling to Rs 2,300 m, at a 14% margin. PAT came in at Rs 710 m against a loss of Rs 340 m in the year-ago quarter. The company welcomed 36.6 m guests during the quarter, up 8% YoY, with ATP at Rs 273 (up 8%) and SPH at Rs 161 (up 9%).
FII stake in PVR INOX rose to 19.1% in the September 2026 quarter. It has moved up from 18.1% in June 2026 to 19.1% in September 2026.
#2 Capri Global Capital
Second on our list is Capri Global.
Capri Global Capital is a retail-focused non-banking financial company incorporated in 1994, headquartered in Mumbai. The company is promoted by Rajesh Sharma, who continues to lead it as Managing Director, Capri has steadily built out into a diversified retail NBFC with a presence in gold loans, MSME lending, housing finance, retail construction finance, car loan distribution and insurance distribution.
The product mix skews heavily toward self-employed and unbanked borrowers in Tier-2, Tier-3 and Tier-4 cities, which is where the company has carved a niche. The business operates through 1,433 branches across 20 states and union territories, serves over 755,000 customers, and has worked to institutionalise its technology stack, including a recent collaboration with OpenAI to bring generative AI across origination, underwriting and collections.
Financial Performance
Capri Global delivered a standout Q1 FY27. Consolidated AUM grew 62% YoY to Rs 4,01,120 m, led by gold loans (+111% YoY), MSME (+24%) and housing finance (+42%). Net interest income rose 79% YoY to Rs 7,360 m, and net profit more than doubled, up 102% YoY to Rs 3,530 m, the highest ever quarterly profit for the company. Asset quality held up, with GNPA at 1.1% and NNPA at 0.6%. RoAA stood at 4.1% and RoAE at 19.1%. CRAR was comfortable at 24.7% at the lender level.
Capri Global Capital Shareholding Pattern
| |
Sep-25 |
Dec-25 |
Mar-26 |
Jun-26 |
Sep-26 |
| Promoters |
60.0% |
59.9% |
59.9% |
59.9% |
59.9% |
| FIIs |
4.8% |
4.5% |
5.6% |
8.2% |
13.0% |
| DIIs |
20.3% |
20.1% |
20.1% |
18.4% |
17.1% |
| Public |
15.0% |
15.5% |
14.3% |
13.5% |
10.0% |
FII Stake Change
FII stake in Capri Global Capital rose sharply to 13.0% in the September 2026 quarter. It has moved up from 8.2% in June 2026 to 13.0% in September 2026, one of the steepest sequential jumps across the midcap NBFC universe.
For more details, see the CAPRI GLOBAL CAPITAL company fact sheet and quarterly results.
#3 Sri Lotus Developers
Next on the list is Sri Lotus Developers.
Sri Lotus Developers and Realty, formerly known as AKP Holdings, is a Mumbai-based luxury and ultra-luxury real estate developer that has quickly built a reputation for premium micro-market execution.
The business model is deliberately asset-light. Close to 100% of new projects are undertaken through redevelopment and joint-development arrangements, which keeps upfront land costs out of the balance sheet and allows the company to focus capital on execution. Projects are typically delivered 12-18 months ahead of RERA timelines, and Lotus commands a 20%-plus premium over peers in the Juhu micro-market on a per-square-foot basis.
Financial Performance
Sri Lotus reported an exceptionally strong Q1 FY27. Pre-sales came in at Rs 4,090 m, up 567% YoY, and collections at Rs 1,500 m, up 115% YoY. Consolidated revenue grew 116% YoY to Rs 1,320 m, EBITDA rose 63% YoY to Rs 480 m at a 36.4% margin, and PAT grew 77% YoY to Rs 460 m, with a PAT margin of 34.5%. The balance sheet remains net cash positive at Rs 6,230 m, with cash of Rs 7,770 m against debt of Rs 1,530 m.
Sri Lotus Developers Shareholding Pattern
| |
Sep-25 |
Dec-25 |
Mar-26 |
Jun-26 |
Sep-26 |
| Promoters |
81.9% |
81.9% |
81.9% |
81.9% |
79.9% |
| FIIs |
2.5% |
1.8% |
1.0% |
1.2% |
4.2% |
| DIIs |
3.1% |
2.8% |
1.6% |
1.7% |
0.9% |
| Public |
12.5% |
13.5% |
15.6% |
15.2% |
15.1% |
FII Stake Change
FII stake in Sri Lotus Developers rose to 4.18% in the September 2026 quarter. It rose from 1.20% in June 2026 to 4.18% in September 2026.
For more details, see the SRI LOTUS DEVELOPERS AND REALTY LTD. company fact sheet and quarterly results.
#4 Granules India
Granules India is a Hyderabad-based pharmaceutical company incorporated in 1991. The company runs a vertically integrated pharma platform spanning APIs, Pharmaceutical Formulation Intermediates (PFIs), Finished Dosages (FDs) and, more recently, Peptide CDMO. North America is its anchor market at roughly 72% of revenue, with Europe and the Rest of the World contributing the balance and growing faster. Granules have been positioning itself as a complex-generics house.
Complex Gx now accounts for around 50% of the finished-dosages portfolio, up from 39% a year ago. In the US, it ranks number one in ten of its 35 products and in the top three in eighteen. It is also the third largest controlled-substance manufacturer in the US by value, having climbed from eighth place in July 2025 on the back of ADHD-focused molecules like Methylphenidate, Dexmethylphenidate, Amphetamines and Lisdexamfetamine.
Financial Performance
Granules had a strong Q1 FY27. Consolidated revenue grew 22% YoY to Rs 14,768 m, EBITDA was up 37% YoY to Rs 3,389 m at a 22.9% margin, and PAT jumped 60% YoY to Rs 1,800 m. Gross margin expanded 74 bps YoY to 65.6%, aided by the complex-generics mix shift. Net debt/EBITDA improved sharply to 0.07x from 0.34x a year earlier, and ROCE rose to 18.0%.
Granules India Shareholding Pattern
| |
Sep-25 |
Dec-25 |
Mar-26 |
Jun-26 |
Sep-26 |
| Promoters |
38.8% |
38.8% |
38.0% |
38.0% |
37.4% |
| FIIs |
14.1% |
13.6% |
15.3% |
17.5% |
20.3% |
| DIIs |
17.9% |
17.5% |
17.0% |
16.1% |
15.3% |
| Public |
29.2% |
30.2% |
29.7% |
28.4% |
27.0% |
FII Stake Change
FII stake in Granules India rose to 20.3% in the September 2026 quarter. It has moved up from 17.5% in June 2026 to 20.3% in September 2026, extending a steady three-quarter trend of foreign accumulation.
For more details, see the GRANULES INDIA company fact sheet and quarterly results.
#5 Akums Drugs & Pharmaceuticals
Finally we have Akums Drugs and Pharmaceuticals.
Akums Drugs and Pharmaceuticals is India's largest pharmaceutical CDMO (contract development and manufacturing) player by revenue, and one of the top three branded formulation CDMOs globally. The business runs eleven manufacturing facilities, with aggregate annual capacity of roughly 5,000 Cr units across oral solids, oral liquids, injectables and topicals. The company serves over 60 geographies and has built out capabilities in differentiated dosage forms including bi-layered tablets, lyophilized vials, pre-filled syringes and gummies. Key accreditations include EU-GMP, US-FDA, NSF, ISO, EFDA and ANVISA, which opens both regulated and semi-regulated export markets.
Financial Performance
Akums delivered a healthy Q1 FY27. Consolidated revenue grew 13.9% YoY to Rs 11,670 m, with EBITDA (including other income) rising 31.7% YoY to Rs 2,050 Mn at a 17.1% margin. PAT came in at Rs 1,010 m, up 56.1% YoY. The CDMO segment, which anchors the business, grew 18.6% YoY to Rs 9,640 m on the back of double-digit volume growth and firmer API prices, with capacity utilisation now at around 50%.
Akums Drugs & Pharmaceuticals Shareholding Pattern
| |
Sep-25 |
Dec-25 |
Mar-26 |
Jun-26 |
Sep-26 |
| Promoters |
75.3% |
75.3% |
75.3% |
75.3% |
75.3% |
| FIIs |
2.3% |
1.1% |
1.4% |
1.9% |
4.5% |
| DIIs |
9.3% |
14.4% |
14.4% |
13.4% |
11.1% |
| Public |
10.5% |
6.5% |
6.3% |
6.7% |
6.4% |
| Others |
2.7% |
2.7% |
2.7% |
2.7% |
2.7% |
FII Stake Change
FII stake in Akums Drugs and Pharmaceuticals stood at 4.5% in the September 2026 quarter, higher versus 1.9% in March 2026. The build-up over the past two quarters reflects a clear re-rating of foreign interest in the name.
For more details, see the AKUMS DRUGS & PHARMACEUTICALS LTD. company fact sheet and quarterly results.
Conclusion
The rise in FII shareholding across PVR INOX, Capri Global Capital, Sri Lotus Developers, Granules India, and Akums Drugs and Pharmaceuticals in the September 2026 quarter is a useful signal, but not a verdict on its own. One quarter of foreign buying rarely tells the full story, and what matters more is whether the operating numbers and promoter commitment hold up in the quarters ahead. Each business carries its own risk, box-office cyclicality at PVR INOX, asset-quality and gold-price swings at Capri Global, project-execution and luxury-demand concentration at Sri Lotus, US pricing pressure at Granules, and API volatility along with acquisition-integration risk at Akums. The broader midcap theme has its own concerns too, with stretched valuations in pockets and the fact that FII flows can reverse just as quickly as they build. The sensible approach is to treat the rise in FII ownership as one input and weigh it against the business model, management quality, balance sheet, valuation, and portfolio fit before drawing any conclusion.
--- Advertisement ---
Investment in securities market are subject to market risks. Read all the related documents carefully before investing
Which businesses are most likely to emerge stronger over the next 3 to 5 years?
After screening thousands of listed companies, comparing industries, and examining balance sheets...
Our research team discovered some of the strongest opportunities in what we call... Essential Stocks.
Opportunities like this do not remain hidden forever.
Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. Learn more about our recommendation services here...
Karthick Gopikumar
Oct 15, 2026Nice Article with more information